An Opinion on the Clinical Laboratory Testing following the New 2021 PNS-Care Diagnostic Criteria

Frykman, H, Kumar, P.  An Opinion on the Clinical Laboratory Testing following the New 2021 PNS-Care Diagnostic Criteria, The Journal of Applied Laboratory Medicine, Volume 7, Issue 1, January 2022, Pages 367–372, https://doi.org/10.1093/jalm/jfab154

Laboratory Testing of Myasthenia Gravis: New Treatments Drive Change

Frykman, H, Kumar, P.  Laboratory Testing of Myasthenia Gravis: New Treatments Drive Change, The Journal of Applied Laboratory Medicine, , jfaa199, https://doi.org/10.1093/jalm/jfaa199

Immunopathology of Autoimmune Myasthenia Gravis: Implications for Improved Testing Algorithms and Treatment Strategies

Frykman, H, Kumar, P, Oger, J.  Immunopathology of Autoimmune Myasthenia Gravis: Implications for Improved Testing Algorithms and Treatment Strategies.  Front. Neurol., 09 December 2020 | https://doi.org/10.3389/fneur.2020.596621

A Multicenter Comparison of MOG-IgG Cell-Based Assays

Waters PJ, Komorowski L, Woodhall M, et al. A multicenter comparison of MOG-IgG cell-based assays. Neurology. 2019;92(11):e1250‐e1255. doi:10.1212/WNL.0000000000007096

Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019;381(7):614‐625. doi:10.1056/NEJMoa1900866

Live-cell Based Assays Are the Gold Standard for anti-MOG-Ab Testing

Yeh EA, Nakashima I. Live-cell based assays are the gold standard for anti-MOG-Ab testing. Neurology. 2019;92(11):501‐502. doi:10.1212/WNL.0000000000007077

MOG Encephalomyelitis: International Recommendations on Diagnosis and Antibody Testing

Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018;15(1):134. Published 2018 May 3. doi:10.1186/s12974-018-1144-2

Multicentre Comparison of a Diagnostic Assay: Aquaporin-4 Antibodies in Neuromyelitis Optica

Waters P, Reindl M, Saiz A, et al. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2016;87(9):1005‐1015. doi:10.1136/jnnp-2015-312601

An Update on Laboratory Diagnosis in Myasthenia Gravis

Oger J, Frykman H. 2015 Sep 20;449:43-8.  doi:10.1016/j.cca.2015.07.030.

Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis

Rodríguez Cruz PM, Al-Hajjar M, Huda S, et al. Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis. JAMA Neurol. 2015;72(6):642‐649. doi:10.1001/jamaneurol.2015.0203

Evaluation of aquaporin-4 antibody assays

Waters PJ, Pittock SJ, Bennett JL, Jarius S, Weinshenker BG, Wingerchuk DM. Evaluation of aquaporin-4 antibody assays. Clin Exp Neuroimmunol. 2014;5(3):290‐303. doi:10.1111/cen3.12107

Clinical and Serological Study of Myasthenia Gravis Using Both Radioimmunoprecipitation and Cell-Based Assays in a South Asian Population

Chang T, Leite MI, Senanayake S, et al. Clinical and serological study of myasthenia gravis using both radioimmunoprecipitation and cell-based assays in a South Asian population. J Neurol Sci. 2014;343(1-2):82-87. doi:10.1016/j.jns.2014.05.037

Detection of anti-natalizumab antibodies in treated multiple sclerosis patients using a BIAcore™ platform

Fronda A, Gibbs E, Aziz T, Oger J (2014).  Detection Of Anti-Natalizumab Antibodies In Treated Multiple Sclerosis Patients Using a Biacore™ Platform (P4.139).   Neurology Apr 2014, 82 (10 Supplement) P4.139;

Late-onset myasthenia gravis: A review when incidence in older adults keeps increasing.

Alkhawajah NM, Oger J. Muscle Nerve. 2013 Nov;48(5):705-10. doi: 10.1002/mus.23964.

NMO-IgG as Measured in Multiple Facilities in Optic Neuritis (ON), Transverse Myelitis and Combinations Thereof

Fronda A, Kuan A, Fritzler M, Fujihara K, Takahashi T. (2012). NMO-IgG as Measured in Multiple Facilities in Optic Neuritis (ON), Transverse Myelitis (TM) and Combinations Thereof (P02.130). Neurology. 78. P02.130-P02.130. 10.1212/WNL.78.1_MeetingAbstracts.P02.130.